Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced that its CEO, Marc N. Casper, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 12:20 p.m. EDT. The presentation will be accessible via a webcast on the company's Investor Relations page. Thermo Fisher Scientific reported annual revenues of approximately $40 billion, focusing on making the world healthier, cleaner, and safer through innovative technologies and pharmaceutical services. For more details, visit www.thermofisher.com.
Thermo Fisher Scientific reported first-quarter 2022 revenue of $11.82 billion, achieving 19% growth year-over-year. The company's GAAP diluted EPS was $5.61, down from $5.88 in Q1 2021, while adjusted EPS rose to $7.25. The results highlighted 16% core organic growth and $1.68 billion from COVID-19 testing. The launch of innovative products and a 15-year collaboration with Moderna for mRNA vaccine manufacturing were key highlights. The company also repurchased $2.0 billion in stock and increased its dividend by 15%.
Portal Innovations has partnered with Life Technologies Corporation, part of Thermo Fisher Scientific (NYSE: TMO), to enhance life sciences research capabilities. This collaboration aims to provide advanced lab equipment and infrastructure to startups at Portal’s 50,000 sq ft facility in Chicago. Patrick Flavin, President of Portal, emphasized that this partnership will allow member companies to accelerate their research and development efforts. Portal focuses on seed investments, management expertise, and access to top-tier lab space to support high-potential life sciences companies.
Thermo Fisher Scientific (NYSE:TMO) will host its 2022 Investor Day on May 18 at 9:00 a.m. (ET), held at Mandarin Oriental New York. The event will feature presentations from senior management and include a Q&A session. Investors can access a live webcast on the company's website, with a replay available later. Thermo Fisher is a global leader in serving science with approximately $40 billion in annual revenue, dedicating efforts to health, safety, and research through innovative technologies and services.
Thermo Fisher Scientific Inc. (NYSE: TMO) will release its financial results for Q1 2022 before the market opens on April 28, 2022, with a conference call scheduled for 8:30 a.m. EST on the same day. The call will outline the company's financial performance and future expectations. Investors can access the call at (844) 200-6205 in the U.S. or (929) 526-1599 internationally, using access code 310385. The press release and additional details will be available on their website.
Thermo Fisher Scientific Inc. (NYSE: TMO) will have its chairman and CEO, Marc N. Casper, present virtually at Cowen’s 42nd Annual Conference on March 7, 2022, at 10:30 a.m. (EST). The conference will be available via webcast on their website. Thermo Fisher, a global leader in serving science, reported annual revenues of approximately $40 billion, supporting advancements in life sciences, diagnostics, and pharmaceutical development.
Thermo Fisher Scientific (NYSE: TMO) has announced a quarterly cash dividend of $0.30 per common share, marking a 15% increase from the previous $0.26. The dividend is payable on April 14, 2022, to shareholders of record as of March 16, 2022. With annual revenues of approximately $40 billion, Thermo Fisher continues to advance its mission of enabling healthier and safer outcomes worldwide.
Moderna and Thermo Fisher Scientific have entered a 15-year strategic collaboration agreement for large-scale manufacturing of mRNA vaccines, including Spikevax®, in the U.S. This partnership aims to enhance manufacturing capacity and efficiency for Moderna's investigational mRNA medicines. Thermo Fisher will provide dedicated aseptic fill-finish services, packaging, and inspection to support Moderna's ongoing development efforts. The collaboration builds on their existing relationship that has successfully supported Moderna's COVID-19 vaccine production.
Thermo Fisher Scientific has expanded its Applied Biosystems portfolio with the new SeqStudio Flex Series Genetic Analyzer, aimed at enhancing clinical research and scientific discovery in areas like gene editing and infectious diseases. This mid-throughput genetic analyzer boasts increased plate capacity, simplified workflows, and advanced Wi-Fi connectivity for remote monitoring. Celebrating 40 years of the Applied Biosystems brand, Thermo Fisher emphasizes ongoing investments in capillary electrophoresis technology, which is central to its sequencing portfolio.
Thermo Fisher Scientific has announced a multiyear partnership with Medidata Acorn AI to develop PPD TrueCast, an advanced platform for enhancing clinical trial performance.
This application integrates machine learning and predictive analytics, leveraging data from over 40,000 trial sites and 50,000 investigators. It aims to optimize site selection, trial enrollment, and study cycle times, potentially reducing Phase III study enrollment by 1.5 months and improving milestone forecasting accuracy by 30%.